Filing Details

Accession Number:
0001493152-24-036461
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-09-16 18:53:39
Reporting Period:
2024-09-12
Accepted Time:
2024-09-16 18:53:39
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1708599 Serina Therapeutics Inc. SER Pharmaceutical Preparations (2834) 821436829
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
2008741 Steven Mintz 601 Genome Way, Suite 2001
Huntsville AL 35806
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-09-12 6,000 $6.47 17,443 No 4 P Indirect By Spouse
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect By Spouse
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 12,257 Direct
Common Stock 3,040 Indirect By Adult Child 1
Common Stock 2,840 Indirect By Adult Child 2
Common Stock 2,650 Indirect By Adult Child 3
Footnotes
  1. The price reflects the weighted average purchase price of multiple transactions. Upon the written request of the SEC, the issuer or a security holder of the issuer, the Reporting Person agrees to provide the number of shares sold at each sale price.
  2. The Reporting Person may be deemed to share voting, investment and dispositive power with respect to these securities. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
  3. The Reporting Person may be deemed to share voting, investment and dispositive power with respect to these securities. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
  4. The Reporting Person may be deemed to share voting, investment and dispositive power with respect to these securities. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.